Efficacy and Safety of Oxytocin in Chronic Neck and Shoulder Pain

Dr Melita Giummarra0 个研究点目标入组 50 人开始时间: 2016年4月26日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Chronic pain participants: English speaking patients aged 18-60 living with musculoskeletal neck and/or shoulder pain that has lasted for at least twelve months and who have been constant in their pain and symptoms for the last 6 months.
•Healthy volunteers will be recruited as control participants and will be subject to the same inclusion/exclusion criteria as the chronic pain participants, with the exception of the presence of the neck and/or shoulder pain.

•Any form of current active treatment (e.g. physiotherapy, manual therapy); past or current history of medical conditions known to affect autonomic functioning (e.g. diabetes, dysthyroidism); past or current history of cancer or other malignancies, asthma or any other chronic respiratory condition, psychological or psychiatric conditions (identified as at risk” of moderate depression, anxiety, or suicidal ideation (as indicated by scores higher than 20 on the Beck Depression Inventory II (BDI-II), scores greater than 15 on the Beck Anxiety Inventory (BAI), or a score of 2 or more on item 9 of the BDI-II)) , alcohol or substance abuse disorders, hypertension or heart disease, neurodegenerative diseases, colour blindness, moderate-severe traumatic brain injury; medications known to affect the autonomic nervous system (e.g. beta blockers, selective serotonin reuptake inhibitors, opioids, benzodiazepines, tricyclic antidepressants, anticholinergics, antiarrhythmics); pregnancy or breastfeeding; any known allergies; incapable of walking; bedridden.
•Healthy volunteers will be recruited as control participants and will be subject to the same inclusion/exclusion criteria as the chronic pain participants, with the exception of the presence of the neck and/or shoulder pain.

发起方

Dr Melita Giummarra